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Background and purpose: To assess and compare the incidence of intra- and extracranial tumours and
mortality in pituitary adenoma patients treated with postoperative radiotherapy and surgery alone.
Patients and methods: A total of 462 pituitary adenoma patients were treated between 1959 and 2008 at
the University Medical Center Groningen in The Netherlands. Postoperative radiotherapy was adminis-
tered on indication in 236 patients.
Results: The median follow-up time was 14 (range 1–49) years in patients treated with radiotherapy and
6 (range 1–34) years in patients treated with surgery alone. Three radiotherapy patients developed an
intracranial tumour compared to one patient treated with surgery alone. The numbers of extracranial
tumours per follow-up year were 6.5 (95% CI 2.5–10.5) and 5.1 (95% CI 1.9–8.2) in patients treated with
and without a technique with vertex ﬁeld and central body axis irradiation and 7.1 (CI 95% 2.9–11.2) in
surgery alone patients. Forty-ﬁve patients treated with radiotherapy died compared to twenty-four
patients treated with surgery alone (log-rank test RR 1.26, 95% CI 0.77–2.08, p = 0.36).
Conclusion: In this study postoperative radiotherapy and a radiotherapy treatment technique with vertex
ﬁeld and central body axis irradiation were not associated with an increased incidence of second tumours
and mortality in pituitary adenoma patients.
 2012 Elsevier Ireland Ltd.Open access under the Elsevier OA license.
Radiotherapy and Oncology 104 (2012) 125–130In most pituitary adenoma patients (non-functioning adenomas
(NFA), growth hormone (GH) secreting and adrenocorticotropic
hormone (ACTH) secreting adenomas), surgery is the treatment
of ﬁrst choice. Postoperative radiotherapy is usually applied in case
of certain indications as an adjuvant treatment modality such as:
(1) in order to prevent tumour progression after incomplete resec-
tion; (2) in case of secreting adenomas where hormonal control
cannot be achieved with surgery alone; and (3) as salvage treat-
ment in case of local recurrence after surgery. Several studies have
shown that postoperative radiotherapy results in an excellent long
term local tumour control with a 10-year progression free survival
of 90–97% [1–5] and an improvement of excessive hormonal secre-
tion [6,7].
Despite the beneﬁts of postoperative radiotherapy regarding
local and hormonal control, the role of radiotherapy has been
debated, in particular because of concerns related to long term side
effects, such as the induction of second tumours and associatedwith
it a negative impact on mortality. Based on these concerns, somediation Oncology, University
anzeplein 1, P.O. Box 30.001,
).
er the Elsevier OA license.investigators proposed to withhold or postpone radiotherapy to
pituitary adenoma patients [8].
In pituitary adenoma patients several studies have reported on
the impact of the disease it self, on the risk of developing tumours
and on mortality. An increased incidence of tumours has been
reported [9,10], as well as an increased incidence of mortality
[11–13]. However, other studies indicated that tumour incidence
[14] and mortality [15,16] were not increased.
Several other investigators evaluated the risk of radiotherapy
on developing second tumours and the impact on mortality in
pituitary adenoma patients. Some reported on an increased risk
for second intracranial [17–19] or extracranial [20] tumours and
an increase in mortality [21,22] in patients treated with surgery
and radiotherapy. However, no ﬁrm support for an increased inci-
dence of second intracranial [20,23] or extracranial [17,19]
tumours and mortality [4,15] was found by others.
All these previous studies compared the incidence of second tu-
mours and mortality in pituitary adenoma patients treated with
surgery and radiotherapy with the incidence observed in a normal
reference population. As a consequence, potential other patient or
treatment related factors that may be responsible for the increased
incidence in tumours and mortality were not taken into account.
126 Pituitary adenoma and radiotherapyTo properly evaluate the concerns related to radiotherapy on
second tumour induction and mortality a direct comparison should
be made with similar patients treated with surgery alone. How-
ever, even in this clinical non-randomisation setting it remains
difﬁcult to prove a causal effect of radiotherapy on second tumour
induction and mortality.
Therefore, the main objective of this study was to assess and
compare the incidence of intra- and extracranial second tumours
and mortality among pituitary adenoma patients treated with
postoperative radiotherapy versus surgery alone.Patients and methods
Patients and follow-up
A total of 462 pituitary adenoma patients (217 males and 245
females) underwent treatment from January 1959 to March 2008
at the University Medical Center Groningen. All patients were
treated with surgery as primary treatment with or without postop-
erative radiotherapy. The patient and treatment characteristics are
shown in Table 1. The diagnosis was based on the patient’s clinical
history and presentation, endocrine evaluation, pituitary imaging,
and all conﬁrmed by histopathological ﬁndings. Ultimately, 256
patients turned out to have a NFA (55%), 139 patients a GH-secret-
ing adenoma (30%), and 67 patients an ACTH-secreting adenoma
(15%), including Cushing’s disease (n = 61) and Nelson’s syndrome
(n = 6).Table 1
Characteristics of the pituitary adenoma patients.
RT+
Number of patients 236
Sex (male/female) 110/12
Age at diagnosis (y)* 46 (10
Age at end of follow-up (y)** 62 (21
Number of patients alive at end of follow-up 191 (8
Duration of follow-up (y)* 14 (1–
Type of adenoma***
Non-functioning adenoma** 143 (6
GH-secreting adenoma 69 (29
ACTH-secreting adenoma** 24 (10
Primary treatment*
Transsphenoidal surgery* 172 (7
Craniotomy* 64 (27
Second surgical treatment 40 (17
Extent of surgery*
Complete resection* 12 (5%
Incomplete resection* 209 (8
Unknown 15 (6%
Postoperative radiotherapy
Age at radiotherapy (y) 49 (19
Time between ﬁrst surgery and RT (y) 1 (1–3
Radiotherapy dose:
644 Gy 4 (2%)
45–49 Gy 173 (7
P50 Gy 55 (23
Unknown 4 (2%)
Radiotherapy technique:
Technique with vertex ﬁeld 80 (34
Technique without vertex ﬁeld 153 (6
Unknown 3 (1%)
Abbreviations: RT+: patients with postoperative radiotherapy; RT: patien
Data are given as absolute numbers, median (range) and percentages.
RT+ versus RT:
* p < 0.001.
** p < 0.01.
*** p < 0.05.Second tumours and death events were retrieved by reviewing
retrospectively the hospital records. The second tumours were
divided in intra- and extracranial tumours.
All patients were followed from the onset of surgery until Janu-
ary 2009 or date of death. For patients who were not seen in the
hospital for follow-up appointments after January 2008 informa-
tion requests were sent to the referring hospital or general practi-
tioner. The median follow-up time after pituitary adenoma
diagnosis for the entire cohort was 9 (range 1–49) years. For
patients treated with radiotherapy this was 14 (range 1–49) years
and 6 (range 1–34) years in patients with surgery alone. The total
follow-up time consisted of 5161 patient-years. For patients trea-
ted with radiotherapy this was 3575 patient-years compared to
1586 patient-years in patients treated with surgery alone. A total
of 202 pituitary adenoma patients (155 radiotherapy and 47 sur-
gery alone patients) were followed-up for more than 10 years.Postoperative radiotherapy
The indication to administer postoperative radiotherapy was
discussed in a multidisciplinary team in which the neurosurgeon,
endocrinologist, radiation oncologist and all other relevant medical
disciplines are involved. The indications for radiotherapy were: (1)
postoperative for local control of tumour growth or hormone ex-
cess in case of residual disease after incomplete resection, or (2)
salvage treatment in patients with recurrent disease after surgery.RT Total
226 462
6 107/119 217/245
–83) 51 (19–81) 47 (10–83)
–89) 57 (23–89) 60 (21–89)
1%) 202 (89%) 393 (85%)
49) 6 (1–34) 9 (1–49)
1%) 113 (50%) 256 (55%)
%) 70 (31%) 139 (30%)
%) 43 (19%) 67 (15%)
3%) 218 (96%) 390 (84%)
%) 8 (4%) 72 (16%)
%) 22 (10%) 62 (14%)
) 117 (52%) 129 (28%)
9%) 95 (42%) 304 (66%)
) 14 (6%) 29 (6%)
–84) – –
2) – –
– –
3%) – –
%) – –
– –
%) – –
5%) – –
– –
ts with surgery alone; y: year; Gy: Gray.
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1959 to 2008, a time period of almost 50 years. Due to improve-
ments over time in neurosurgery treatment and better imaging
techniques (CT/MRI), less postoperative radiotherapy was needed
and the indication for postoperative radiotherapy declined.
External beam radiotherapy was applied in 143 (61%) patients
with a NFA, 69 (29%) patients with a GH-secreting adenoma and
in 24 (10%) patients with an ACTH-secreting adenoma. All radio-
therapy data were retrieved from the individual radiotherapy
patient charts. The median radiation dose was 45 Gy (range 30–
55 Gy). Most patients received a radiation fractionation scheme
of 25 daily fractions of 1.8 Gy in 5 weeks.
Patients were treated with radiotherapy from 1962 to 2008.
One patient was treated with 200 kV X-rays and two patients with
Cobalt-60. All other patients were treated with external beam
radiotherapy with 4–18 MeV photons.
The radiation dose to the tumour was prescribed at the tumour
encompassing isodose in the time period 1962–1990. From 1991 to
2008 the dose was prescribed at a central point in the tumour
according to the recommendations of the International Commis-
sion on Radiation Units and Measurements.
In the time period 1962–2008 different radiotherapy tech-
niques were used for the treatment of pituitary adenoma. Some
techniques included a vertex ﬁeld with a radiation beam conﬁgu-
ration entering through the top of the head. As a consequence, the
entire axial length of the body is irradiated and various extracranial
organs may be exposed to radiotherapy and possibly increasing
the chances of developing second extracranial tumours [24]. For
this reason, the radiotherapy patients were divided into a group
irradiated with (n = 80) or without (n = 153) a radiotherapy
technique with vertex ﬁeld and central body axis irradiation. The
incidence of extracranial tumours was assessed and compared be-
tween these two radiotherapy groups and the surgery alone group.Statistical methods
The incidence of second tumours occurring after pituitary ade-
noma diagnosis in patients treated with postoperative radiother-
apy were compared to patients treated with surgery alone.
Because the surgery alone patients did not receive radiotherapy,
registration of tumours started from the date of pituitary adenoma
diagnosis, allowing a direct comparison of both treatments from a
ﬁxed point in time.
A left-censored log-rank test with stratiﬁcation for sex was used
for investigating the risk for tumours.
The number of second tumours per follow-up year were calcu-
lated per treatment group because of differences in time of follow-
up between patients treated with postoperative radiotherapy and
surgery alone.
To answer the question if patients treated with radiotherapy
have an increased overall mortality compared to patients treated
with surgery alone, death events in pituitary adenoma patientsTable 2
Characteristics of the individual pituitary adenoma patients diagnosed with intracranial tu
Type of
intracranial
tumour
Type of
adenoma
Sex Age at pituitary
adenoma diagnosis
Age at intracran
tumour diagnos
Meningioma NFA M 42 56
Meningioma GH F 36 57
NFA metastasis NFA M 25 37
Glioblastoma
multiforme
NFA F 50 56
Abbreviations: RT: radiotherapy; F: female; M: male; Y: yes; NFA: non-functioning adenom
this patient was treated with surgery alone.who received radiotherapy were compared to patients who under-
went surgery alone. Both treatment groups were compared to an
age and sex related reference population according to the stan-
dardized mortality rate (SMR). SMR is a ratio between observed
and expected numbers of death events. The expected death events
were calculated using the annual published life tables of the
Central Ofﬁce of Statistics (CBS) accounting for year of birth and
gender (http://www.cbs.nl). Age at diagnosis was transformed to
median life expectancy (MLE) using the annual life tables of the
CBS according to gender. MLE at pituitary adenoma diagnosis in
patients treated with radiotherapy were compared to the patients
treated with surgery alone with the Mann–Whitney-U test.
There is an inverse correlation between age and life expectancy.
Therefore, in the time to event analysis of longitudinal follow-up,
the age at start of follow-up must be taken into consideration. In
conventional methods like Cox regression analysis and log-rank
test this problem is solved by using age as an independent risk
factor. However, because age is related to other risk factors of life
expectancy, such as gender and year of birth, it is unclear to what
extent this correction for age is related to life expectancy and to
what extent to these other risk factors. To avoid this methodolog-
ical bias it is recommended to use age itself instead of surviving
time as the time base in analyses [25]. This way, participants of
the same age are compared. Additionally, by using age as the time
scale, control for calendar period and/or birth cohort effects can be
achieved by stratifying the model on birth cohort. Age at the event
(death or second tumour) instead of surviving time is the outcome
parameter.
Because of the difference in age at start of follow-up, left-cen-
soring is used: the patient is only used in the calculations after
reaching the age at start of follow-up. Also right-censoring is
applied: the patient does not participate in the analyses at ages
higher than that at the end of follow-up.
Cox-regression analysis, log-rank test and Kaplan–Meier curves
can be performed without objection this way.
A log-rank test was used to calculate the relative risk of death
events in patients treated with postoperative radiotherapy
compared to patients treated with surgery alone.
Data are expressed as mean ± SD, median (interquartile range)
or percentages when appropriate. Two-tail p-values <0.05 were
considered signiﬁcant. SPSS 16.0 and Excel 2003 were used for data
analysis.Results
Incidence of intracranial tumours
Four (two males and two females) out of 462 pituitary adenoma
patients developed an intracranial tumour after pituitary adenoma
diagnosis (Table 2).
Three intracranial tumours (1.3%) developed in patients treated
with postoperative radiotherapy compared to one intracranialmour and treated with postoperative radiotherapy or surgery alone.
ial
is
Time since RT
in years
Total pituitary RT
dose in Gray
No. of RT
ﬁelds
Location in
RT ﬁeld
14 50 2 and 5 Y
20 50 3 Y
10 45 5 Y
N/A N/A N/A N/A
a; GH: growth-hormone; ACTH: adrenocorticotropic hormone; N/A: not applicable,
00.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 20 40 60 80 100
Age
C
um
ul
at
iv
e 
Pr
op
or
tio
n
Age at pituitary adenoma diagnosis in postoperative radiotherapy patients.
Age at pituitary adenoma diagnosis in surgery alone patients.
Age at tumour diagnosis in postoperative radiotherapy patients.
128 Pituitary adenoma and radiotherapytumour (0.4%) in a patient treated with surgery alone. These num-
bers were too small for statistical analysis on extent of exposure
between the two treatment groups.
Two patients treated with postoperative radiotherapy devel-
oped meningiomas. Both patients received radiotherapy after
incomplete resection and were treated with a total radiotherapy
dose of 50 Gy in daily fractions of 2 Gy. The NFA patient had a
localized right fronto-parietal meningioma at a scar place at the
skull from the right-sided craniotomy procedure. This patient
was operated upon and 11 years after surgery, no evidence of
recurrence of meningioma was seen on magnetic resonance (MR)
imaging. The GH-secreting adenoma patient had a 1.5 cm large
meningioma located at the processus clinoideus anterior on the left
side. Repeated MR imaging during a 9 year follow-up period
revealed no evidence of progression. Both patients were alive at
the end of follow-up of this study.
A tumour at the skull base was found in one male NFA patient
10 years after radiotherapy because of an incomplete resection.
This patient received a total dose of 45 Gy in daily fractions of
1.8 Gy. Histological analysis after surgery showed a metastasis of
NFA without malignant transformation. At the end of follow-up
of this study, and 7 years later after the diagnosis of metastasis
of NFA, this patient was still alive.
One female NFA patient developed a glioblastoma multiforme
after treatment with surgery alone. The diagnosis was conﬁrmed
histologically. She died of glioblastoma multiforme 7 months after
the initial diagnosis.
None of these 4 patients were diagnosed with extracranial
tumours.Age at tumour diagnosis in surgery alone patients.
Fig. 1. Age at pituitary adenoma diagnosis and age at tumour diagnosis in patients
treated with postoperative radiotherapy compared to patients treated with surgery
alone.Incidence of extracranial tumours
Thirty-one (16 males and 15 females) of the 462 patients devel-
oped 33 extracranial tumours after the date of pituitary adenoma
diagnosis (Supplementary material).
Twenty patients (11 males and 9 females) treated with postop-
erative radiotherapy were diagnosed with a total of 22 extracranial
tumours compared to eleven patients treated with surgery alone
(Supplementary material). The number of extracranial tumours
per follow-up year were 6.5 (95% CI 2.5–10.5) in patients treated
with a radiotherapy technique with a vertex ﬁeld and central body
axis irradiation compared to 5.1 (95% CI 1.9–8.2) in patients trea-
ted without a radiotherapy technique with vertex ﬁeld and central
body axis irradiation and 7.1 (CI 95% 2.9–11.2) in patients treated
with surgery alone.
Two radiotherapy patients developed each two extracranial
tumours. The ﬁrst was a male GH-secreting adenoma patient
who developed a basal cell carcinoma located at the hairy part of
the head at an age of 59 years 13 years after radiotherapy. At the
age of 73 years he was diagnosed with metastatic melanoma of un-
known primary origin 26 years after radiotherapy. The second
ACTH-secreting female adenoma patient developed a basal cell car-
cinoma at the back 9 years after radiotherapy at an age of 47 years
and a second basal cell carcinoma located at the ﬂank one year
later. Both patients had been treated with a radiotherapy tech-
nique with vertex ﬁeld and central body axis irradiation with a to-
tal radiotherapy dose of 45 Gy in daily fractions of 1.8 Gy.
The age at pituitary adenoma diagnosis and age at tumour diag-
nosis is shown in Fig. 1 for patients treated with postoperative
radiotherapy compared to patients treated with surgery alone.Incidence of death events
Sixty-nine out of 462 patients died during follow-up. In 236
postoperative radiotherapy patients 45 deaths were observed com-
pared to 41.26 expected and in 226 surgery alone patients 24deaths were observed compared to 27.74 expected (log-rank test
RR 1.26, 95% CI 0.77–2.08, p = 0.36). Age at pituitary adenoma diag-
nosis and age at death is shown in Fig. 2 for patients treated with
postoperative radiotherapy compared to patients treated with
surgery alone and compared to the expected age of death in the
Dutch reference population. There was an increased incidence of
death events in the entire study population compared to an age
and sex related Dutch reference population (SMR 1.47, 95% CI
1.18–1.75, p = 0.0016; Fig. 2).Discussion
This study did not demonstrate that postoperative radiotherapy
in pituitary adenoma patients has a negative impact on the inci-
dence of second intra- and extracranial tumours and mortality
compared to patients treated with surgery alone. First, three intra-
cranial tumours developed in patients treated with radiotherapy
compared to one tumour in a patient treated with surgery alone,
which numbers were too small for statistical analysis on extent
of exposure. Lack of signiﬁcance does not mean that there is no dif-
ference between treatment with postoperative radiotherapy or
surgery alone but that the differences and absolute risk between
the treatment groups on developing an intracranial tumour is
small. Second, the yearly incidence of extracranial tumours was
not different in patients treated with surgery alone compared to
patients treated with postoperative radiotherapy. Moreover, a
radiotherapy technique with a vertex ﬁeld and central body axis
irradiation was not associated with an increased incidence of sec-
ond extracranial tumours. Finally, this study showed a slightly in-
creased incidence of death events in the entire study population
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Fig. 2. Age at pituitary adenoma diagnosis and age at death in patients treated with
postoperative radiotherapy compared to patients treated with surgery alone and
compared to the expected age of death in the Dutch reference population.
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There was no difference in death events in patients treated with
radiotherapy compared to patients treated with surgery alone.
In the present study the median follow-up time for patients
treated with postoperative radiotherapy was 14 (range 1–49) years
compared to 6 (range 1–34) years in patients treated with surgery
alone. Despite a longer follow-up time for patients treated with
radiotherapy no difference was seen in the incidence of second
tumours or death events between the two treatment groups.
In previous studies the incidence of second tumours and mor-
tality in pituitary adenoma patients treated with radiotherapy
were compared with a normal reference population instead of
patients treated with surgery alone.
Our results conﬁrm those of other investigators who did not
ﬁnd an increased incidence of intracranial tumours in patients
treated with surgery and radiotherapy compared to a reference
population with a median follow-up time of 8 (range 0.08–28)
and 14 (range 0.1–38) years [20,23]. However, Brada et al. reported
a cumulative risk of intracranial tumours after radiotherapy, rang-
ing from 1.3% to 2% over the ﬁrst 10 years and from 1.9% to 2.4%
over the ﬁrst 20 years [17,19]. The relative risk for developing
intracranial tumours in patients treated with radiotherapy was
9.4 (95% CI 3.1–22) compared to that observed in a normal refer-
ence population. Eleven of the 426 patients (2.6%) developed a sec-
ond intracranial tumour (5 meningioma’s, 4 gliomas, 1 meningeal
sarcoma and 1 primitive neuroectodermal tumour). The median
follow-up time was 12 (range 0–38) years [19]. A study by Tsang
et al. reported a cumulative risk of second glioma after radiother-
apy of 1.7% at 10 years and 2.7% at 15 years [18]. The relative risk
of developing a malignant brain tumour was 16 (95% CI 4.4–41).Four of the 305 irradiated patients (1.3%) developed gliomas of
the brain. The median follow-up time was 7.9 (range 0.1–19.7)
years [18].
These studies do not provide sound evidence that radiotherapy
per se is the only causal factor because the comparison with regard
to the incidence of brain tumours were made with the general pop-
ulation instead of non-irradiated pituitary adenoma patients.
Moreover, the absolute observed numbers in these studies are
small and based on a few incident cases (2.6% and 1.3%) and are
accompanied by wide conﬁdence intervals.
In the present study two patients treated with radiotherapy
developed a meningioma and one patient developed a metastasis
of a NFA. Meningiomas are the most common diagnosed second
intracranial tumours after cranial radiotherapy, mainly developed
in patients irradiated in childhood for brain tumours, leukaemia
and tinea capitis [26,27]. Radiation-induced meningioma differs
from ‘‘spontaneous meningiomas’’ with regard to the patient’s
age at diagnosis, location, multiplicity, aggressive biological behav-
iour and the rate of tumour recurrence [27,28]. Spontaneous
meningiomas are generally diagnosed in the 5th or 6th decade of
life while radiation-induced meningioma presents at a younger
age with incidence peaks in the second and third decade of life
[26,27]. In this study, the age of meningioma diagnosis was
56 years for the NFA patient and 57 years for the GH-secreting pa-
tient and developed at 14 and 20 years after radiotherapy. There is
a tendency for shorter latency in patients treated with higher doses
and larger treatment volumes [26,27]. Although the median fol-
low-up time of 14 years in this study might be short to develop
meningioma, it is comparable to the study by Erfurth et al. [23]
who did not ﬁnd an increased incidence of intracranial tumours,
and has a longer median follow-up time compared to the studies
by Brada et al. [19] and Tsang et al. [18] who did ﬁnd an increased
incidence of intracranial tumours. The meningiomas diagnosed in
our study may represent a late complication of postoperative
radiotherapy. However, a higher incidence of second intracranial
tumours could also be explained by a genetic trait that predisposes
to both pituitary adenomas and intracranial tumours. This hypoth-
esis is supported by the ﬁndings of Jones et al. that reported on the
co-occurrence of glioma or meningioma in pituitary adenoma pa-
tients treated with surgery alone [29]. In the present study one
NFA patient developed a glioblastoma multiforme 6 years after
treatment with surgery alone. In the patients treated with surgery
alone meningioma was not diagnosed. In the patient with a metas-
tasis of NFA the role of radiotherapy in the development of metas-
tasis of NFA without malignant transformation is unknown
because of this extreme rare disease.
Our results on extracranial tumours conﬁrm those of other
investigators who reported no excess risk of second extracranial
tumours in patients treated with radiotherapy compared to inci-
dence rates observed in a reference population [17,19]. However,
in the study by Bliss et al. 30 extracranial tumours were diagnosed
out of 269 pituitary adenoma patients treated with radiotherapy
compared with an expected incidence of 17.5 (95% CI 12–26,
p < 0.01) in an age and gender-matched population. The pituitary
adenoma patients were treated with two lateral opposed ﬁelds or
an anterior and two lateral opposed ﬁelds. The reporting of second
extracranial tumours was possibly more complete than in the ref-
erence population due to regular review.
This study showed no difference in death events in patients
treated with postoperative radiotherapy compared to patients
treated with surgery alone. Postoperative radiotherapy in pituitary
adenoma patients is given on indication as an adjuvant treatment
after surgery. The purpose of the study was to compare death
events between patients treated with postoperative radiotherapy
and surgery alone and therefore the cause of death was irrelevant.
The results of this study regarding a slightly increased incidence of
130 Pituitary adenoma and radiotherapydeath events in the entire study population irrespective of
treatment compared to an age and sex related Dutch reference
population can be explained by the uncontrolled disease itself in
some patients, like in acromegaly and Cushing’s disease, and hypo-
pituitarism [11–13,30,31] in both treatment groups.
In conclusion, in this current study postoperative radiotherapy
for pituitary adenoma patients was not associated with an
increased incidence of second tumours and mortality compared
to patients who are treated with surgery alone. Furthermore, a
radiotherapy technique with a vertex ﬁeld and central body axis
irradiation was not associated with an excess risk of second extra-
cranial tumours. In patients treated with radiotherapy second
tumours registration requires lifelong follow-up and a consequent
documentation in cancer registries as well as registration of tu-
mours in patients treated with surgery alone. In most cases the
beneﬁts of postoperative radiotherapy outweigh the absolute small
risk of second tumour induction. We believe that postoperative
radiotherapy should therefore not be avoided as an adjuvant treat-
ment modality to pituitary adenoma patients with otherwise
uncontrolled disease who can beneﬁt from it.
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